Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 19, 2015 09:43 ET | Source: Genmab A/S

De amerikanske sundhedsmyndigheder tildeler Priority Review-status til ofatumumab som vedligeholdelsesbehandling af recidiverende CLL

Selskabsmeddelelse FDA i USA tildeler Priority Review-status for supplerende registreringsansøgning for ofatumumab som vedligeholdelsesbehandling af recidiverende CLL PDUFA dato sat til den...
September 19, 2015 09:43 ET | Source: Genmab A/S

U.S. FDA Grants Priority Review for Ofatumumab as Maintenance Therapy for Relapsed CLL

Company Announcement U.S. FDA grants Priority Review to sBLA for ofatumumab as maintenance therapy in relapsed CLL PDUFA target date has been set to January 21, 2016 Copenhagen, Denmark;...
September 09, 2015 10:05 ET | Source: Genmab A/S

Genmab præsenterer ved Morgan Stanley 2015 Global Healthcare konference

Pressemeddelelse København, Danmark, 9. september 2015 – Genmab A/S (OMX: GEN) offentliggjorde i dag, at selskabets CEO, Jan van de Winkel, ph.d. vil give en præsentation om selskabet ved Morgan...
September 09, 2015 10:05 ET | Source: Genmab A/S

Genmab to Present at the 2015 Morgan Stanley Global Healthcare Conference

Media Release Copenhagen, Denmark; September 9, 2015 – Genmab A/S (OMX: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the Morgan Stanley Global...
September 09, 2015 07:28 ET | Source: Genmab A/S

Genmab meddeler, at der er indsendt registreringsansøgning i Europa for daratumumab til behandling af dobbelt-refraktær myelomatose

Selskabsmeddelelse Janssen har indsendt markedsføringsansøgning til EMA for daratumumab til behandling af myelomatose Ansøgningen er primært baseret på data fra fase II studiet (Sirius...
September 09, 2015 07:28 ET | Source: Genmab A/S

Genmab Announces European Regulatory Submission for Daratumumab in Double Refractory Multiple Myeloma

Company Announcement MAA submitted to EMA by Janssen for daratumumab in multiple myeloma Submission mainly based on data from Phase II study (Sirius MMY2002) Copenhagen, Denmark;...
September 04, 2015 14:11 ET | Source: Genmab A/S

U.S. FDA Grants Priority Review for Daratumumab for Double Refractory Multiple Myeloma

Company Announcement U.S. FDA grants Priority Review to daratumumab PDUFA target date has been set to March 9, 2016 Copenhagen, Denmark; September 4, 2015 – Genmab A/S (OMX: GEN)...
September 04, 2015 14:11 ET | Source: Genmab A/S

De amerikanske sundhedsmyndigheder tildeler Priority Review-status til daratumumab i dobbelt-refraktær myelomatose

Selskabsmeddelelse FDA i USA tildeler Priority Review-status til daratumumab PDUFA dato fastsat til 9. marts 2016 København, Danmark; 4. september 2015 – Genmab A/S (OMX: GEN) har i dag...
September 02, 2015 16:06 ET | Source: Genmab A/S

Storaktionærmeddelelse

Selskabsmeddelelse Storaktionærmeddelelse for Genmab A/S København, Danmark, 2. september 2015 – Genmab A/S (OMX: GEN) skal under henvisning til Værdipapirlovens paragraf 29 meddele, at FIL...
September 02, 2015 16:06 ET | Source: Genmab A/S

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; September 2, 2015 – Genmab A/S (OMX: GEN) announces under reference to Section 29 of the Danish...